Trv Gp V LLC Makes New $10.47 Million Investment in Maze Therapeutics, Inc. (NASDAQ:MAZE)

Key Points

• Trv Gp V LLC acquired 950,800 shares of Maze Therapeutics for approximately $10.5 million, making it the third largest position in their portfolio.
• Shares of Maze Therapeutics saw a decline of 1.8% and are currently trading at $14.25, with a yearly high of $19.19.
• Maze Therapeutics reported a loss of ($1.15) EPS for the recent quarter, missing analysts' expectations, and has a consensus rating of "Buy" with a target price of $25.60.

TRV GP V LLC purchased a new position in Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 950,800 shares of the company's stock, valued at approximately $10,468,000. Maze Therapeutics makes up about 8.4% of TRV GP V LLC's investment portfolio, making the stock its 3rd largest holding. TRV GP V LLC owned 2.17% of Maze Therapeutics as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in MAZE. New York State Common Retirement Fund purchased a new stake in shares of Maze Therapeutics during the 1st quarter worth approximately $25,000. Bank of New York Mellon Corp bought a new position in shares of Maze Therapeutics during the 1st quarter valued at approximately $190,000. Charles Schwab Investment Management Inc. bought a new position in shares of Maze Therapeutics during the 1st quarter valued at approximately $796,000. Bessemer Group Inc. bought a new position in shares of Maze Therapeutics during the 1st quarter valued at approximately $5,305,000. Finally, Harvard Management Co. Inc. bought a new position in shares of Maze Therapeutics during the 1st quarter valued at approximately $7,019,000.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Wedbush began coverage on Maze Therapeutics in a research report on Tuesday, July 8th. They set an "outperform" rating and a $17.00 target price on the stock. HC Wainwright assumed coverage on Maze Therapeutics in a research report on Wednesday, July 23rd. They set a "buy" rating and a $34.00 price target on the stock. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $25.60.

Maze Therapeutics Price Performance

Shares of NASDAQ MAZE traded up $0.29 during midday trading on Monday, hitting $13.43. The stock had a trading volume of 44,615 shares, compared to its average volume of 201,183. Maze Therapeutics, Inc. has a 1 year low of $6.71 and a 1 year high of $19.19. The company's 50 day simple moving average is $13.90.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($1.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.39).

Maze Therapeutics Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.